<DOC>
	<DOCNO>NCT00199043</DOCNO>
	<brief_summary>In study efficacy tolerability two approach treat prevent hyperuricemia test patient acute lymphoblastic leukemia high-grade lymphoma high risk tumor lysis syndrome . Both arm compare randomisation . In one arm patient receive pre-phase chemotherapy conventional prophylaxis allopurinol whereas arm Rasburicase use .</brief_summary>
	<brief_title>Treatment Hyperuricemia With Rasburicase Patients With Acute Lymphoblastic Leukemia High Grade Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>patient GMALL BALL/NHLStudy 2002 patient GMALLStudy 07/2003 patient GMALLStudy Elderly 1/2003 fulfill follow criterion : bulky disease ( &gt; 7.5 cm ) high LDH ( &gt; 2 x UNL ) uric acid &gt; 8 mg/dl/ &gt; 475µmol/L diagnosis leukocyte &gt; 30 000/µl exclusion Criteria GMALL BALL/NHL Study 2002 GMALLStudy 07/2003 GMALLElderly 1/2003 : asthma severe , livethreatening atopic allergy history hypersensitivity Uric acid Glucose6PhosphateDehydrogenase deficiency pretreatment Rasburicase Urikozyme™</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>